How It Works Sleep Regulation: DSIP promotes slow-wave (delta) sleep, which is essential for physical recovery, hormone balance, and immune function
In developing the data elements for submission and process for voluntary submission to the repository, we considered how to minimize burden on covered entities
Following single dose of subcutaneous administration of 1.28 mg of EGRIFTA WR (11.6 mg/vial formulation) in healthy subjects, the mean [coefficient of variation (CV)] AUC0-inf was 1172 (48%) pg.h/mL
Safety depends on the compound, dose, route, and product purity
Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling
